Drug-Coated Balloons Versus Drug-Eluting Stents for Multivessel Coronary Artery Disease
Compares two ways of opening narrowed heart arteries in people with multivessel coronary artery disease.
Key facts
- Who runs it
- Genoss Co., Ltd.
- Where
- Ulsan, South KoreaSee the site
- Trial code
- Registry title
- Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
- Status
- Recruiting
- People taking part
- 892 people, planned
- Started
- 28 Sept 2026
- Expected to end
- 31 Dec 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)
- Contemporary Drug-Eluting Stents (DES)
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowing in at least two main heart arteries who need a catheter procedure (PCI) to open them. It compares a drug-coated balloon with a drug-eluting stent.
- Age
- 20 years or older
- Sex
- All sexes can join
- Disease stage
- Multivessel coronary artery disease: at least 50% narrowing in 2 or more main heart arteries. Stable angina, silent ischemia, unstable angina or NSTEMI can join. After a STEMI, only if the first PCI worked well, at least 48 hours have passed, and there is no clot in the lesion. The treated vessel is 2.25 mm to 4.0 mm wide.
- Earlier treatment
- After a STEMI, a successful and uncomplicated first PCI is required, at least 48 hours before.
Main reasons for not taking part
- Cardiogenic shock or need for circulatory support
- Life expectancy of 2 years or less
- Taking part in another interventional trial
- Pregnant women or women who could become pregnant
- Allergy to contrast media or to materials or drugs used in the devices (such as paclitaxel or sirolimus)
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients must meet all of the following inclusion criteria to be eligible for participation in this clinical study
- Adults aged ≥20 years with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI)
- Patients with ST-segment elevation myocardial infarction (STEMI) who have undergone successful and uncomplicated primary percutaneous coronary intervention (PCI), are at least 48 hours after the index procedure, and have no evidence of thrombus in the lesion(s) intended for treatment
- Patients with multivessel coronary artery disease, defined as ≥50% diameter stenosis by coronary angiography, in whom the investigator determines that PCI is indicated in at least two major epicardial coronary arteries
- Patients with a reference vessel diameter (RVD) of ≥2.25 mm and ≤4.0 mm, as assessed by coronary angiography
- Patients in whom the investigator determines, based on coronary angiographic findings and clinical assessment, that PCI of the target lesion(s) is technically feasible
- Patients who voluntarily provide written informed consent to participate in the clinical trial and are willing and able to comply with the study requirements
Who cannot take part
- Life expectancy of ≤2 years due to concomitant medical conditions
- Known hypersensitivity or allergy to contrast media, L-605 cobalt-chromium (Co-Cr) alloy, PLA or PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus
- Patients in whom the investigator determines that PCI cannot be performed because of the anatomical characteristics of the target vessel or lesion or the patient's clinical condition
- Patients meeting any of the following criteria will be excluded from enrollment
- Cardiogenic shock or the need for mechanical or pharmacological circulatory support
- Current participation in, or planned participation in, another interventional clinical trial, excluding observational studies
- Pregnant women or women of childbearing potential
- A target lesion located within a saphenous vein graft or an arterial graft
Where in South Korea
- Ulsan University HospitalUlsan, South KoreaContact: Eun-Seok Shin, MD, PhDTaking people
About the trial
What the trial wants to find out
This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.
The 2 groups in the trial
- GENOSS® DCBTreatment being tested
Paclitaxel-coated PTCA Balloon Catheter
Treatment: GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)
- Contemporary Drug-Eluting Stents (DES)Existing treatment, for comparison
All-comer current-generation biodegradable or durable polymer-based drug-eluting stents (DES)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Impact of Drug-Coated-Balloon-based Versus Drug-Eluting-Stent-based Intervention in Patients With Multivessel Coronary Artery Disease : A Prospective, Multicenter, Active-controlled, Randomized, Single-blind, Investigator-initiated Clinical Trial
- Plain-language title
- Drug-Coated Balloons Versus Drug-Eluting Stents for Multivessel Coronary Artery DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 9 October 2026